International seed major Limagrain has entered into a global licensing agreement with Beijing Qi Biodesign Biotechnology Co., Ltd. (Qi Biodesign) to access a portfolio of advanced genome editing technologies.
The strategic agreement grants France-headquartered Limagrain immediate rights to Qi Biodesign's proprietary genome editing tools, including a novel CRISPR nuclease platform, across its global field crop and vegetable seed research programmes. The framework also enables Limagrain to integrate future developments from Qi Biodesign's research pipeline into its plant breeding operations.
The collaboration aims to accelerate the commercial development of high-performing crop varieties capable of addressing climate stress, evolving disease pressures, and rising environmental sustainability requirements.
Kevin Zhao, Chief Executive Officer and Co-Founder of Qi Biodesign, added that the collaboration marks a major step in deploying the company's proprietary genome editing technologies across global crop research. Zhao highlighted that combining Qi Biodesign's tools with Limagrain's global seed infrastructure will accelerate the commercialisation of improved crop varieties.
Next-Generation Plant Breeding and CRISPR Tools
Genome editing represents a significant evolution in modern plant breeding, transitioning beyond first-generation CRISPR applications toward multi-tool platforms designed for complex traits.
By integrating Qi Biodesignâs technology suite, Limagrain expands its research infrastructure to tackle multi-gene traits and specific breeding hurdles across diverse crop families.
Key operational focus areas of the licensing agreement include:
𧏠CRISPR Nuclease Access: Immediate access to Qi Biodesign's novel CRISPR nuclease platform, enhancing targeted gene insertion and trait editing precision.
đ± Multi-Crop Deployment:Â Application of genome editing tools across both high-volume field crops and commercial vegetable seed lines.
đ Pipeline Synergy:Â A formalised framework ensuring Limagrain receives access to upcoming intellectual property and gene editing innovations developed by Qi Biodesign.
New Genomic Techniques
The timing of the partnership aligns with ongoing legislative developments within the European Union regarding New Genomic Techniques (NGTs). European regulatory frameworks are shifting toward updated policy environments for gene-edited crops, creating commercial pathways for NGT-derived seeds across continental Europe.
By combining elite germplasm with advanced gene editing tools, seed producers are positioning their product pipelines to supply European and global farmers with crop varieties optimised for input efficiency and climate resilience.
SĂ©bastien Chauffaut, Chief Executive Officer of Limagrain and Chairman of the Scientific Committee, stated that the future of plant breeding relies on scientific excellence, technological diversity, and strategic partnerships. Chauffaut noted that broadening access to complementary gene editing tools strengthens the group's capacity to develop resilient crop varieties for global agricultural challenges.
Limagrain:Â Founded as an agricultural cooperative in France, Limagrain is an international seed and agri-food group employing approximately 9,600 people across 53 countries. The group breeds, produces, and commercialises field seeds and vegetable seeds, alongside operating integrated agri-food processing divisions.
Qi Biodesign:Â Beijing Qi Biodesign Biotechnology Co., Ltd. is a Chinese biotechnology firm specialising in the research, development, and application of proprietary genome editing systems and advanced plant breeding platforms.
.jpg)
